Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 5:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,101 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Brain (Nervous System) Cancers Clear all
Completed Not applicable Interventional

In-Room PET in Proton Radiation Therapy

NCT01228448
View directory record Official record
Conditions
Brain Tumor, Head and Neck Tumor, Skull Base Tumor
Interventions
PET scan
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 7, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic Radiosurgery

NCT02097732
View directory record Official record
Conditions
Metastatic Melanoma, Brain Metastases
Interventions
Ipilimumab, Stereotactic Radiosurgery
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 7, 2026, 5:18 AM EDT
Active, not recruiting Not applicable Interventional

Proton Radiation Therapy for Gliomas

NCT01358058
View directory record Official record
Conditions
Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation, WHO Grade 3 Glioma With 1p/19q Codeletion
Interventions
Proton radiation
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Oct 7, 2026, 5:18 AM EDT
Completed No phase listed Observational

Chemotherapeutic Agents in Brain/Breast

NCT00795678
View directory record Official record
Conditions
Breast Cancer, Metastatic Cancer
Interventions
capecitabine, cyclophosphamide, doxorubicin hydrochloride, gemcitabine hydrochloride, lapatinib ditosylate, paclitaxel, vinorelbine ditartrate, Trastuzumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 2, 2013 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Not applicable Interventional

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

NCT02440906
View directory record Official record
Conditions
Chronic Mental Illness, Chronic Physical Illness
Interventions
Patient-Directed Wellness Account, Health Navigator
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 55 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 7, 2026, 5:18 AM EDT
Withdrawn Not applicable Interventional

Neurocognitive Outcomes In Patients Treated With Radiotherapy For Five Or More Brain Metastases

NCT01731704
View directory record Official record
Conditions
Brain Metastases
Interventions
Stereotactic radiosurgery (SRS), Whole brain radiation therapy (WBRT)
Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2017 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 1Phase 2 Interventional

Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors

NCT00005952
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor
Interventions
filgrastim, temozolomide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Duke University
Other
Eligibility
Up to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 7, 2026, 5:18 AM EDT
Withdrawn Phase 2 Interventional

Efficacy of Acetaminophen in Posterior Fossa Surgery

NCT02532322
View directory record Official record
Conditions
Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions
IV acetaminophen, normal saline
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
2 Years to 12 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 8, 2021 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas

NCT00002965
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Recombinant Interferon Alfa (INF alpha)
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 1 Interventional

Phase I Study of Safety and Immunogenicity of ADU-623

NCT01967758
View directory record Official record
Conditions
Astrocytic Tumors, Glioblastoma Multiforme, Anaplastic Astrocytoma, Brain Tumor
Interventions
Cohort 1, Cohort 2, Cohort 3, Antibiotics
Biological · Drug
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 17, 2018 · Synced Oct 7, 2026, 5:18 AM EDT
Recruiting Not applicable Interventional

Systematic Light Exposure in Pediatric Brain Tumor Survivors

NCT05340881
View directory record Official record
Conditions
Brain Tumor
Interventions
Bright Light Exposure, Dim Light Exposure, Cognitive Assessment
Behavioral · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Chemotherapy and HAART to Treat AIDS-related Primary Brain Lymphoma

NCT00267865
View directory record Official record
Conditions
AIDS-Related-Primary Central Nervous System Lymphoma
Interventions
Methotrexate, Rituximab, Leucovorin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2020 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional

Prinomastat Plus Temozolomide Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00004200
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
prinomastat, temozolomide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 8, 2012 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study of Modified Atkins Ketogenic Diet in the Treatment of Newly Diagnosed Malignant Glioma

NCT03278249
View directory record Official record
Conditions
Glioblastoma
Interventions
Modified Atkins Ketogenic Diet
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

NCT02681549
View directory record Official record
Conditions
Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
Interventions
Pembrolizumab plus Bevacizumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 7, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

Phase I Study of Marizomib + Panobinostat for Children With DIPG

NCT04341311
View directory record Official record
Conditions
Diffuse Intrinsic Pontine Glioma, Pediatric Brainstem Glioma, Pediatric Brainstem Gliosarcoma, Recurrent, Pediatric Cancer, Pediatric Brain Tumor, Diffuse Glioma
Interventions
Marizomib, Panobinostat
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Up to 21 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Ph. 2 Sorafenib + Protracted Temozolomide in Recurrent GBM

NCT00597493
View directory record Official record
Conditions
Recurrent Glioblastoma Multiforme
Interventions
Sorafenib and Temozolomide
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 7, 2026, 5:18 AM EDT
Active, not recruiting Phase 1 Interventional

GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases

NCT04192981
View directory record Official record
Conditions
Brain Metastases, Leptomeningeal Metastasis
Interventions
GDC-0084, whole brain radiation therapy radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 7, 2026, 5:18 AM EDT
Terminated No phase listed Observational

Methionine and PBR28-PET (Peripheral Benzodiazepine Receptors) in Brain Metastases Following Radiosurgery

NCT02433171
View directory record Official record
Conditions
Brain Metastasis
Interventions
Standard of Care FDG-PET Imaging
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 80 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 28, 2019 · Synced Oct 7, 2026, 5:18 AM EDT
Active, not recruiting Phase 2 Interventional

Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome

NCT03604198
View directory record Official record
Conditions
Cushing Syndrome
Interventions
relacorilant
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
25
States / cities
Phoenix, Arizona • Stanford, California • Torrance, California + 21 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 7, 2026, 5:18 AM EDT
Terminated Phase 1 Interventional

Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

NCT00003567
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, sargramostim, therapeutic autologous lymphocytes, O6-benzylguanine, carmustine, temozolomide, in vitro-treated peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 7, 2026, 5:18 AM EDT
Terminated Phase 2 Interventional Results available

Imaging of Intravenous (IV) Combidex to Brain, Intra-cerebral Tumors and in Central Nervous System (CNS) Inflammation

NCT00659334
View directory record Official record
Conditions
Brain Neoplasms
Interventions
Ferumoxtran-10 (Combidex), Neurosurgery
Drug · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
5 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 7, 2026, 5:18 AM EDT
Completed Phase 2 Interventional Results available

Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

NCT00445965
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin), Metastatic Cancer, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Small Intestine Cancer
Interventions
DNA analysis, immunologic technique, pharmacological study, iodine I 131 monoclonal antibody 3F8, 131I-3F8
Genetic · Other · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 7, 2026, 5:18 AM EDT
Active, not recruiting Not applicable Interventional

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy

NCT05703269
View directory record Official record
Conditions
NSCLC, Renal Cell Carcinoma, Breast Carcinoma, Melanoma, Brain Metastases, Adult, Non-small Cell Lung Cancer, SCLC, Small-cell Lung Cancer
Interventions
single fraction stereotactic radiosurgery (SSRS), fractionated stereotactic radiosurgery (FSRS)
Radiation
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
34
States / cities
Savannah, Georgia • Decatur, Illinois • Effingham, Illinois + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 7, 2026, 5:18 AM EDT